Literature DB >> 23796475

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.

Tamar Kapanadze1, Jaba Gamrekelashvili, Chi Ma, Carmen Chan, Fei Zhao, Stephen Hewitt, Lars Zender, Veena Kapoor, Dean W Felsher, Michael P Manns, Firouzeh Korangy, Tim F Greten.   

Abstract

BACKGROUND & AIMS: Myeloid derived suppressor cells (MDSC) are immature myeloid cells with immunosuppressive activity. They accumulate in tumor-bearing mice and humans with different types of cancer, including hepatocellular carcinoma (HCC). The aim of this study was to examine the biology of MDSC in murine HCC models and to identify a model, which mimics the human disease.
METHODS: The comparative analysis of MDSC was performed in mice, bearing transplantable, diethylnitrosoamine (DEN)-induced and MYC-expressing HCC at different ages.
RESULTS: An accumulation of MDSC was found in mice with HCC irrespective of the model tested. Transplantable tumors rapidly induced systemic recruitment of MDSC, in contrast to slow-growing DEN-induced or MYC-expressing HCC, where MDSC numbers only increased intra-hepatically in mice with advanced tumors. MDSC derived from mice with subcutaneous tumors were more suppressive than those from mice with DEN-induced HCC. Enhanced expression of genes associated with MDSC generation (GM-CSF, VEGF, IL6, IL1β) and migration (MCP-1, KC, S100A8, S100A9) was observed in mice with subcutaneous tumors. In contrast, only KC levels increased in mice with DEN-induced HCC. Both KC and GM-CSF overexpression or anti-KC and anti-GM-CSF treatment controlled MDSC frequency in mice with HCC. Finally, the frequency of MDSC decreased upon successful anti-tumor treatment with sorafenib.
CONCLUSIONS: Our data indicate that MDSC accumulation is a late event during hepatocarcinogenesis and differs significantly depending on the tumor model studied. Published by Elsevier B.V.

Entities:  

Keywords:  BLR; Cancer vaccine; DEN; G-CSF; GM-CSF; HCC; IL; Immunotherapy; KC; L-NMMA; LAP; MCP; MDSC; N(G)-methyl-L-arginine; N(ω)-hydroxil-nor-L-arginine; N-NOHA; NK; OVA; Tumor immunology; VEGF; WT; body weight/liver weight ratio; diethylnitrosoamine; granulocyte colony stimulating factor; granulocyte-macrophage colony stimulating factor; hepatocellular carcinoma; iNOS; inducible nitric oxide synthase; interleukin; keratinocyte-derived chemokine; liver activator protein; macrophage chemotactic protein; myeloid derived suppressor cell; natural killer; ovalbumin; vascular endothelial growth factor; wild type

Mesh:

Substances:

Year:  2013        PMID: 23796475      PMCID: PMC3805787          DOI: 10.1016/j.jhep.2013.06.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

1.  Serum cytokine levels in patients with hepatocellular carcinoma.

Authors:  Francesca Capone; Susan Costantini; Eliana Guerriero; Rosa Calemma; Maria Napolitano; Stefania Scala; Francesco Izzo; Giuseppe Castello
Journal:  Eur Cytokine Netw       Date:  2010-05-18       Impact factor: 2.737

2.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.

Authors:  Zhongwei Cao; Hua Fan-Minogue; David I Bellovin; Aleksey Yevtodiyenko; Julia Arzeno; Qiwei Yang; Sanjiv Sam Gambhir; Dean W Felsher
Journal:  Cancer Res       Date:  2011-01-24       Impact factor: 12.701

3.  CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.

Authors:  Lydia A Haile; Jaba Gamrekelashvili; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

Review 4.  Myeloid derived suppressor cells in human diseases.

Authors:  Tim F Greten; Michael P Manns; Firouzeh Korangy
Journal:  Int Immunopharmacol       Date:  2011-01-13       Impact factor: 4.932

5.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

Review 6.  Subsets, expansion and activation of myeloid-derived suppressor cells.

Authors:  Eliana Ribechini; Verena Greifenberg; Sarah Sandwick; Manfred B Lutz
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

7.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Authors:  Cesar A Corzo; Thomas Condamine; Lily Lu; Matthew J Cotter; Je-In Youn; Pingyan Cheng; Hyun-Il Cho; Esteban Celis; David G Quiceno; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

8.  Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.

Authors:  Michael K Connolly; Jon Mallen-St Clair; Andrea S Bedrosian; Ashim Malhotra; Valery Vera; Junaid Ibrahim; Justin Henning; H Leon Pachter; Dafna Bar-Sagi; Alan B Frey; George Miller
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

9.  Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice.

Authors:  Liang Cheng; Jun Wang; Xiaozhu Li; Qiao Xing; Peishuang Du; Lishan Su; Shengdian Wang
Journal:  PLoS One       Date:  2011-03-04       Impact factor: 3.240

10.  Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

Authors:  Mengde Cao; Yiling Xu; Je-in Youn; Roniel Cabrera; Xiaokui Zhang; Dmitry Gabrilovich; David R Nelson; Chen Liu
Journal:  Lab Invest       Date:  2011-02-14       Impact factor: 5.662

View more
  77 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

2.  Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Zachary J Brown; Su Jong Yu; Bernd Heinrich; Chi Ma; Qiong Fu; Milan Sandhu; David Agdashian; Qianfei Zhang; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Immunother       Date:  2018-06-29       Impact factor: 6.968

Review 3.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

4.  Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Authors:  José Medina-Echeverz; Chi Ma; Austin G Duffy; Tobias Eggert; Nga Hawk; David E Kleiner; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Res       Date:  2015-01-30       Impact factor: 11.151

5.  Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Authors:  Steven L Highfill; Yongzhi Cui; Amber J Giles; Jillian P Smith; Hua Zhang; Elizabeth Morse; Rosandra N Kaplan; Crystal L Mackall
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

6.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.

Authors:  Pin Wu; Dang Wu; Chao Ni; Jun Ye; Wuzhen Chen; Guoming Hu; Zhen Wang; Changrong Wang; Zhigang Zhang; Wenjie Xia; Zhigang Chen; Ke Wang; Tao Zhang; Jinghong Xu; Yuehua Han; Ting Zhang; Xianguo Wu; Jianwei Wang; Weihua Gong; Shu Zheng; Fuming Qiu; Jun Yan; Jian Huang
Journal:  Immunity       Date:  2014-05-08       Impact factor: 31.745

Review 8.  Myeloid cells in hepatocellular carcinoma.

Authors:  Shanshan Wan; Ning Kuo; Ilona Kryczek; Weiping Zou; Theodore H Welling
Journal:  Hepatology       Date:  2015-07-01       Impact factor: 17.425

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

10.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.